Do analysts prefer LMNX or HBIO?

Harvard Bioscience has a consensus target price of $6.00, suggesting a potential downside of 6.72%. Given Harvard Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Harvard Bioscience is more favorable than Defiance Daily Target 2X Long LMND ETF. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Defiance Daily Target 2X Long LMND ETF 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Harvard Bioscience 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer TMO or HBIO?

In the previous week, Thermo Fisher Scientific had 32 more articles in the media than Harvard Bioscience. MarketBeat recorded 34 mentions for Thermo Fisher Scientific and 2 mentions for Harvard Bioscience. Thermo Fisher Scientific's average media sentiment score of 1.49 beat Harvard Bioscience's score of 0.00 indicating that Thermo Fisher Scientific is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Thermo Fisher Scientific 30 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Harvard Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer A or HBIO?

In the previous week, Agilent Technologies had 2 more articles in the media than Harvard Bioscience. MarketBeat recorded 4 mentions for Agilent Technologies and 2 mentions for Harvard Bioscience. Agilent Technologies' average media sentiment score of 1.21 beat Harvard Bioscience's score of 0.00 indicating that Agilent Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilent Technologies 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harvard Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, WAT or HBIO?

Waters has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Waters $3.17B 11.52 $642.63M $7.87 47.18 Harvard Bioscience $85.53M 0.34 -$56.70M -$2.17 N/A

Does the media prefer WAT or HBIO?

In the previous week, Waters had 2 more articles in the media than Harvard Bioscience. MarketBeat recorded 4 mentions for Waters and 2 mentions for Harvard Bioscience. Waters' average media sentiment score of 0.16 beat Harvard Bioscience's score of 0.00 indicating that Waters is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Waters 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harvard Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ILMN or HBIO?

In the previous week, Illumina had 20 more articles in the media than Harvard Bioscience. MarketBeat recorded 22 mentions for Illumina and 2 mentions for Harvard Bioscience. Illumina's average media sentiment score of 0.80 beat Harvard Bioscience's score of 0.00 indicating that Illumina is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Illumina 12 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Harvard Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Harvard Bioscience (HBIO) Competitors

$6.43 -0.20 (-2.99%)

As of 09:37 AM Eastern

Compare

HBIO vs. LMNX, TMO, A, WAT, and ILMN

Should you buy Harvard Bioscience stock or one of its competitors? MarketBeat compares Harvard Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Harvard Bioscience include Defiance Daily Target 2X Long LMND ETF (LMNX), Thermo Fisher Scientific (TMO), Agilent Technologies (A), Waters (WAT), and Illumina (ILMN). These companies are all part of the "life sciences tools & services" industry.

How does Harvard Bioscience compare to Defiance Daily Target 2X Long LMND ETF?

Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap life sciences tools & services companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, Harvard Bioscience had 2 more articles in the media than Defiance Daily Target 2X Long LMND ETF. MarketBeat recorded 2 mentions for Harvard Bioscience and 0 mentions for Defiance Daily Target 2X Long LMND ETF. Defiance Daily Target 2X Long LMND ETF's average media sentiment score of 0.00 equaled Harvard Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Defiance Daily Target 2X Long LMND ETF	Neutral
Harvard Bioscience	Neutral

Defiance Daily Target 2X Long LMND ETF has a beta of 7.95, suggesting that its share price is 695% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Defiance Daily Target 2X Long LMND ETF has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Defiance Daily Target 2X Long LMND ETF, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Defiance Daily Target 2X Long LMND ETF	$437.66M	0.02	$15.17M	$0.51	40.00
Harvard Bioscience	$85.53M	0.34	-$56.70M	-$2.17	N/A

87.8% of Defiance Daily Target 2X Long LMND ETF shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 6.6% of Defiance Daily Target 2X Long LMND ETF shares are held by company insiders. Comparatively, 20.3% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Harvard Bioscience has a consensus target price of $6.00, suggesting a potential downside of 6.72%. Given Harvard Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Harvard Bioscience is more favorable than Defiance Daily Target 2X Long LMND ETF.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Defiance Daily Target 2X Long LMND ETF	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Defiance Daily Target 2X Long LMND ETF has a net margin of 5.39% compared to Harvard Bioscience's net margin of -11.44%. Defiance Daily Target 2X Long LMND ETF's return on equity of 4.66% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Defiance Daily Target 2X Long LMND ETF	5.39%	4.66%	2.91%
Harvard Bioscience	-11.44%	-25.78%	-4.37%

Summary

Defiance Daily Target 2X Long LMND ETF beats Harvard Bioscience on 9 of the 15 factors compared between the two stocks.

How does Harvard Bioscience compare to Thermo Fisher Scientific?

Thermo Fisher Scientific (NYSE:TMO) and Harvard Bioscience (NASDAQ:HBIO) are both life sciences tools & services companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

In the previous week, Thermo Fisher Scientific had 32 more articles in the media than Harvard Bioscience. MarketBeat recorded 34 mentions for Thermo Fisher Scientific and 2 mentions for Harvard Bioscience. Thermo Fisher Scientific's average media sentiment score of 1.49 beat Harvard Bioscience's score of 0.00 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Thermo Fisher Scientific	30 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Harvard Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Thermo Fisher Scientific has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

Thermo Fisher Scientific currently has a consensus price target of $601.61, indicating a potential upside of 18.14%. Harvard Bioscience has a consensus price target of $6.00, indicating a potential downside of 6.72%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, equities research analysts plainly believe Thermo Fisher Scientific is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Thermo Fisher Scientific	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

89.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by company insiders. Comparatively, 20.3% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Thermo Fisher Scientific has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Thermo Fisher Scientific	$44.56B	4.25	$6.70B	$18.19	28.00
Harvard Bioscience	$85.53M	0.34	-$56.70M	-$2.17	N/A

Thermo Fisher Scientific has a net margin of 15.15% compared to Harvard Bioscience's net margin of -11.44%. Thermo Fisher Scientific's return on equity of 16.86% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Thermo Fisher Scientific	15.15%	16.86%	8.15%
Harvard Bioscience	-11.44%	-25.78%	-4.37%

Summary

Thermo Fisher Scientific beats Harvard Bioscience on 15 of the 17 factors compared between the two stocks.

How does Harvard Bioscience compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Harvard Bioscience (NASDAQ:HBIO) are both life sciences tools & services companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Agilent Technologies currently has a consensus price target of $160.88, suggesting a potential upside of 25.35%. Harvard Bioscience has a consensus price target of $6.00, suggesting a potential downside of 6.72%. Given Agilent Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Agilent Technologies is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Agilent Technologies has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Agilent Technologies has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	5.22	$1.30B	$4.98	25.77
Harvard Bioscience	$85.53M	0.34	-$56.70M	-$2.17	N/A

Agilent Technologies has a net margin of 19.55% compared to Harvard Bioscience's net margin of -11.44%. Agilent Technologies' return on equity of 24.33% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.55%	24.33%	12.99%
Harvard Bioscience	-11.44%	-25.78%	-4.37%

80.9% of Harvard Bioscience shares are owned by institutional investors. 20.3% of Harvard Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Agilent Technologies had 2 more articles in the media than Harvard Bioscience. MarketBeat recorded 4 mentions for Agilent Technologies and 2 mentions for Harvard Bioscience. Agilent Technologies' average media sentiment score of 1.21 beat Harvard Bioscience's score of 0.00 indicating that Agilent Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harvard Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Agilent Technologies beats Harvard Bioscience on 14 of the 17 factors compared between the two stocks.

How does Harvard Bioscience compare to Waters?

Waters (NYSE:WAT) and Harvard Bioscience (NASDAQ:HBIO) are both life sciences tools & services companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Waters has a net margin of 11.91% compared to Harvard Bioscience's net margin of -11.44%. Waters' return on equity of 15.60% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Waters	11.91%	15.60%	8.90%
Harvard Bioscience	-11.44%	-25.78%	-4.37%

In the previous week, Waters had 2 more articles in the media than Harvard Bioscience. MarketBeat recorded 4 mentions for Waters and 2 mentions for Harvard Bioscience. Waters' average media sentiment score of 0.16 beat Harvard Bioscience's score of 0.00 indicating that Waters is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Waters	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harvard Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Waters has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Waters	$3.17B	11.52	$642.63M	$7.87	47.18
Harvard Bioscience	$85.53M	0.34	-$56.70M	-$2.17	N/A

Waters presently has a consensus target price of $399.84, suggesting a potential upside of 7.70%. Harvard Bioscience has a consensus target price of $6.00, suggesting a potential downside of 6.72%. Given Waters' stronger consensus rating and higher probable upside, equities analysts clearly believe Waters is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Waters	0 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.77
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Waters has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

94.0% of Waters shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 0.3% of Waters shares are held by company insiders. Comparatively, 20.3% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Waters beats Harvard Bioscience on 15 of the 17 factors compared between the two stocks.

How does Harvard Bioscience compare to Illumina?

Illumina (NASDAQ:ILMN) and Harvard Bioscience (NASDAQ:HBIO) are both life sciences tools & services companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

In the previous week, Illumina had 20 more articles in the media than Harvard Bioscience. MarketBeat recorded 22 mentions for Illumina and 2 mentions for Harvard Bioscience. Illumina's average media sentiment score of 0.80 beat Harvard Bioscience's score of 0.00 indicating that Illumina is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Illumina	12 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Harvard Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Illumina has a net margin of 19.42% compared to Harvard Bioscience's net margin of -11.44%. Illumina's return on equity of 31.01% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Illumina	19.42%	31.01%	12.22%
Harvard Bioscience	-11.44%	-25.78%	-4.37%

Illumina has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Illumina	$4.34B	6.64	$850M	$5.50	34.68
Harvard Bioscience	$85.53M	0.34	-$56.70M	-$2.17	N/A

89.4% of Illumina shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 2.9% of Illumina shares are held by insiders. Comparatively, 20.3% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Illumina presently has a consensus price target of $148.94, suggesting a potential downside of 21.91%. Harvard Bioscience has a consensus price target of $6.00, suggesting a potential downside of 6.72%. Given Harvard Bioscience's higher probable upside, analysts plainly believe Harvard Bioscience is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Illumina	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Illumina has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

Summary

Illumina beats Harvard Bioscience on 13 of the 16 factors compared between the two stocks.

Get Harvard Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HBIO vs. The Competition

Export

Metric	Harvard Bioscience	INSTRU Industry	Computer Sector	NASDAQ Exchange
Market Cap	$29.64M	$1.59B	$39.02B	$12.57B
Dividend Yield	N/A	0.32%	3.18%	6.50%
P/E Ratio	-3.03	3.77	77.86	24.41
Price / Sales	0.34	1.28	601.92	117.36
Price / Cash	0.54	8.30	46.23	57.41
Price / Book	2.10	2.67	9.54	6.40
Net Income	-$56.70M	-$10.45M	$1.07B	$331.37M
7 Day Performance	6.31%	8.28%	-1.95%	-0.91%
1 Month Performance	7.02%	4.58%	-1.18%	1.88%
1 Year Performance	40.34%	-2.31%	138.94%	22.83%

Harvard Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HBIO Harvard Bioscience	0.8694 of 5 stars	$6.43 -3.0%	$6.00 -6.7%	+49.7%	$29.64M	$85.53M	N/A	490	News Coverage Gap Down
LMNX Defiance Daily Target 2X Long LMND ETF	N/A	$16.35 +8.7%	N/A	N/A	$5.40M	$437.66M	32.06	1,325
TMO Thermo Fisher Scientific	4.8486 of 5 stars	$500.36 -1.2%	$605.09 +20.9%	+23.2%	$185.94B	$44.56B	27.51	125,000	Positive News Analyst Forecast
A Agilent Technologies	4.901 of 5 stars	$132.80 0.0%	$160.88 +21.1%	+10.2%	$37.51B	$7.23B	26.67	18,100	Positive News
WAT Waters	2.1438 of 5 stars	$375.90 +1.9%	$396.68 +5.5%	+8.3%	$36.91B	$3.17B	47.76	7,900	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HBIO) was last updated on 7/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harvard Bioscience (HBIO) Competitors

HBIO vs. LMNX, TMO, A, WAT, and ILMN

How does Harvard Bioscience compare to Defiance Daily Target 2X Long LMND ETF?

Summary

How does Harvard Bioscience compare to Thermo Fisher Scientific?

Summary

How does Harvard Bioscience compare to Agilent Technologies?

Summary

How does Harvard Bioscience compare to Waters?

Summary

How does Harvard Bioscience compare to Illumina?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harvard Bioscience (HBIO) Competitors

HBIO vs. LMNX, TMO, A, WAT, and ILMN

How does Harvard Bioscience compare to Defiance Daily Target 2X Long LMND ETF?

Does the media favor LMNX or HBIO?

Which has more risk and volatility, LMNX or HBIO?

Which has stronger valuation & earnings, LMNX or HBIO?

Do insiders & institutionals have more ownership in LMNX or HBIO?

Do analysts prefer LMNX or HBIO?

Is LMNX or HBIO more profitable?

Summary

How does Harvard Bioscience compare to Thermo Fisher Scientific?

Does the media prefer TMO or HBIO?

Which has more risk and volatility, TMO or HBIO?

Do analysts rate TMO or HBIO?

Do institutionals and insiders hold more shares of TMO or HBIO?

Which has better valuation & earnings, TMO or HBIO?

Is TMO or HBIO more profitable?

Summary

How does Harvard Bioscience compare to Agilent Technologies?

Do analysts rate A or HBIO?

Which has more risk and volatility, A or HBIO?

Which has stronger earnings and valuation, A or HBIO?

Is A or HBIO more profitable?

Do institutionals and insiders have more ownership in A or HBIO?

Does the media prefer A or HBIO?

Summary

How does Harvard Bioscience compare to Waters?

Is WAT or HBIO more profitable?

Does the media prefer WAT or HBIO?

Which has higher earnings & valuation, WAT or HBIO?

Do analysts prefer WAT or HBIO?

Which has more volatility and risk, WAT or HBIO?

Do institutionals and insiders hold more shares of WAT or HBIO?

Summary

How does Harvard Bioscience compare to Illumina?

Does the media prefer ILMN or HBIO?

Is ILMN or HBIO more profitable?

Which has higher valuation and earnings, ILMN or HBIO?

Do institutionals & insiders hold more shares of ILMN or HBIO?

Do analysts recommend ILMN or HBIO?

Which has more volatility and risk, ILMN or HBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools